ArticleScientific reports2025
Acteoside ameliorates cerebral ischemia/reperfusion injury in MCAO rats as a natural plasma Kallikrein inhibitor from Osmanthus fragrans flower.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Overcoming Oxidative Stress in Parkinson's Disease: NADPH Oxidase 4 (NOX4) as a Potential Therapeutic Target.Antioxidants (Basel, Switzerland) · 2026Review
- Effects and Mechanisms of Dietary Natural Products on Ischemic Stroke: An Updated Review.Food science & nutrition · 2025Review
- Hypericin alleviates cerebral ischemia/reperfusion injury by modulating endoplasmic reticulum stress.Frontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Acteoside is the potential bioactive component of Osmanthus fragrans flowers for treating stroke. However, the pharmacological actions, therapeutic targets and underlying mechanisms of acteoside in cerebral ischemia/reperfusion injury remain poorly understood. In this study, we investigated the therapeutic effect, direct target, and the underlying mechanisms of acteoside on cerebral I/R injury in middle cerebral artery occlusion (MCAO) rats. Our study suggested that treatment with OFFE or acteoside significantly reduced cerebral infarct area in MCAO rats. Coagulation function measurement suggested that acteoside treatment increased activated partial thromboplastin time (APTT) and prothrombin time (PT) in vitro. Further molecular docking and enzyme activity assays indicated that acteoside binds to plasma kallikrein (pKal) and markedly inhibits its activity. RNA sequencing, ELISA, and Western blotting revealed that acteoside regulated coagulation to mitigate inflammation by modulating NF-κB signaling and inhibite oxidative stress by suppressing NOX2/NOX4 pathways. These findings reveal that acteoside exerts protective effects against cerebral I/R injury in MCAO rats by attenuating inflammation and oxidative stress as a natural plasma kallikrein inhibitor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.